262MO Multi-omics signature for identification of RAS wild-type colorectal cancer liver metastases sensitive to anti-EGFR therapy

Abstract

There are nearly half patients with Ras wild-type metastatic colorectal cancer (mCRC) do not response to Anti-EGFR therapy. Identification of patients who are sensitive to anti-EGFR therapy may increase the response rate and reduce the adverse effect. Therefore, there is a pressing need for predicting the efficacy and the clinical benefit in RAS wild type patients. In this study, we aimed to develop and validate a multi-omics deep learning model to predict cetuximab efficacy in RAS wild type mCRC patients.